Research programme: T cell receptor cancer therapeutics - Kite Pharma/Leiden University Medical Center

Drug Profile

Research programme: T cell receptor cancer therapeutics - Kite Pharma/Leiden University Medical Center

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kite Pharma; Leiden University Medical Center
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Cell replacements; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 13 May 2016 9195659- relevant info already updated
  • 13 Jan 2016 Kite Pharma and Leiden University Medical Center agree to co-develop T-cell receptor therapeutics for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top